Echincaea Calendula
- Manufacturer
- Uriel Pharmacy Inc.
- Effective date
- 2017-07-27
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:14:36
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR TOPICAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Apply to skin as needed. Under age 2: Consult a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: 100gm contains: 30gm Echinacea (Purple coneflower) 1X, 15gm Calendula 1X, 5gm Resina laricis (Larch resin) 1X; Viscum Mali (Apple tree mistletoe) 3X, Cuprum aceticum (Copper acetate) 6X, Argentum metallicum (Silver) 7X, Cutis - feti (Porcine skin) 8X, Funiculus umbilicalis (Bovine umbilical cord) 8X, Placenta - bovis (Bovine placenta) 8X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Distilled water, Glycerin, Sodium alginate, Rosemary oil, Potassium sorbate, Grapefruit seed extract
OTC - PURPOSE SECTION
Uses: Soothes delicate skin, supports slowly healing wounds and strengthens skin regeneration.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: FOR EXTERNAL USE ONLY.
Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions, if conditions worsen or persist, or accidental ingestion occurs. If pregnant or nursing, consult a doctor before use. Avoid contact with eyes. Do not use if safety seal is broken or missing.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858 Made with care by Uriel, East Troy, WI 53120
www.urielpharmacy.com
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BOS TAURUS PLACENTA | ACTIVE INGREDIENT | 83AL37E3A7 | 1 | |
| CALENDULA OFFICINALIS FLOWERING TOP | ACTIVE INGREDIENT | 18E7415PXQ | 1 | |
| CUPRIC ACETATE | ACTIVE INGREDIENT | 39M11XPH03 | 1 | |
| ECHINACEA, UNSPECIFIED | ACTIVE INGREDIENT | 4N9P6CC1DX | 1 | |
| LARIX DECIDUA RESIN | ACTIVE INGREDIENT | AD8LJ73GQF | 1 | |
| SILVER | ACTIVE INGREDIENT | 3M4G523W1G | 1 | |
| SUS SCROFA SKIN | ACTIVE INGREDIENT | 3EM4VW6TQN | 1 | |
| SUS SCROFA UMBILICAL CORD | ACTIVE INGREDIENT | 118OYG6W3H | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE INGREDIENT | BK9092J5MP | 1 | |
| BOS TAURUS PLACENTA | ACTIVE MOIETY | 83AL37E3A7 | 1 | |
| CALENDULA OFFICINALIS FLOWERING TOP | ACTIVE MOIETY | 18E7415PXQ | 1 | |
| CUPRIC CATION | ACTIVE MOIETY | 8CBV67279L | 1 | |
| ECHINACEA, UNSPECIFIED | ACTIVE MOIETY | 4N9P6CC1DX | 1 | |
| LARIX DECIDUA RESIN | ACTIVE MOIETY | AD8LJ73GQF | 1 | |
| SILVER | ACTIVE MOIETY | 3M4G523W1G | 1 | |
| SUS SCROFA SKIN | ACTIVE MOIETY | 3EM4VW6TQN | 1 | |
| SUS SCROFA UMBILICAL CORD | ACTIVE MOIETY | 118OYG6W3H | 1 | |
| VISCUM ALBUM FRUITING TOP | ACTIVE MOIETY | BK9092J5MP | 1 | |
| CITRUS PARADISI SEED | INACTIVE INGREDIENT | 12F08874Y7 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 1 | |
| ROSEMARY OIL | INACTIVE INGREDIENT | 8LGU7VM393 | 1 | |
| SODIUM ALGINATE | INACTIVE INGREDIENT | C269C4G2ZQ | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- Echincaea Calendula
- Echinacea Calendula
- WATER
- GLYCERIN
- SODIUM ALGINATE
- ROSEMARY OIL
- POTASSIUM SORBATE
- CITRUS PARADISI SEED
- ECHINACEA, UNSPECIFIED
- CALENDULA OFFICINALIS FLOWERING TOP
- LARIX DECIDUA RESIN
- VISCUM ALBUM FRUITING TOP
- CUPRIC ACETATE
- CUPRIC CATION
- SILVER
- SUS SCROFA SKIN
- SUS SCROFA UMBILICAL CORD
- BOS TAURUS PLACENTA
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-4135 | 48951-4135-5 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| SODIUM ALGINATE | C269C4G2ZQ | IACT |
| ROSEMARY OIL | 8LGU7VM393 | IACT |
| POTASSIUM SORBATE | 1VPU26JZZ4 | IACT |
| CITRUS PARADISI SEED | 12F08874Y7 | IACT |
| ECHINACEA, UNSPECIFIED | 4N9P6CC1DX | ACTIB |
| CALENDULA OFFICINALIS FLOWERING TOP | 18E7415PXQ | ACTIB |
| LARIX DECIDUA RESIN | AD8LJ73GQF | ACTIB |
| VISCUM ALBUM FRUITING TOP | BK9092J5MP | ACTIB |
| CUPRIC ACETATE | 39M11XPH03 | ACTIB |
| SILVER | 3M4G523W1G | ACTIB |
| SUS SCROFA SKIN | 3EM4VW6TQN | ACTIB |
| SUS SCROFA UMBILICAL CORD | 118OYG6W3H | ACTIB |
| BOS TAURUS PLACENTA | 83AL37E3A7 | ACTIB |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | MOUTHWASH / BUCCAL | 100 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / ORAL | 750 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TROCHE / ORAL | 525 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / RECTAL | 6.67 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | CAPSULE / ORAL | 160 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / VAGINAL | 227.9 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | POWDER, FOR SUSPENSION / ORAL | 19 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | LOTION / TOPICAL | 0.2 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SPRAY, METERED / NASAL | 0.06 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY / NASAL | 22.3 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / DENTAL | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, FILM COATED / ORAL | 1.55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRADERMAL | 1.6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CREAM / TOPICAL | 0.25 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SUSPENSION / ORAL | 400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 225 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION, CONCENTRATE / ORAL | 200 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE / ORAL | 3487 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, EXTENDED RELEASE / ORAL | 265 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SYRUP / ORAL | 2 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TABLET, EXTENDED RELEASE / ORAL | 627 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | SUSPENSION / ORAL | 49 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | LOZENGE / ORAL | 1274 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, COATED / ORAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CONCENTRATE / ORAL | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| bd212235-529a-df7d-e053-2995a90ac214 | cbf20918-1f29-4b66-9d99-78a09adf986a | 2021-03-09 | Warnings | cbf20918-1f29-4b66-9d99-78a09adf986a |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
